Entrada Therapeutics, Inc. SEC Filings

Entrada Therapeutics, Inc. (TRDA)November 20, 2025, the funds bought multiple blocks of Entrada common stock, including 1,213 and 1,186 shares at weighted-average prices of $9.0688 and $9.0728, respectively. Additional blocks of 13,386 and 13,082 shares were also acquired at the same respective weighted-average prices.

After these trades, one indirect holding reported in Table I rose to 380,152 shares of common stock and a second to 381,338 shares, with larger indirect positions of 4,678,310 and 4,691,392 shares reported for other related entities. The filing explains that Baker Brothers’ principals and advisory entities may be deemed to have indirect pecuniary interests through their limited partnership and advisory relationships, while expressly disclaiming beneficial ownership beyond their economic interests.

Entrada Therapeutics (TRDA) reported an insider share sale by a major holder. On 11/14/2025, an entity affiliated with director and 10% owner Kush M. Parmar, M.D., Ph.D., sold 200,000 shares of Entrada Therapeutics common stock in an open-market transaction at a weighted average price of $8.80 per share, with individual sale prices ranging from $8.80 to $9.023.

Following this transaction, 5AM Ventures V, L.P. is shown as beneficially owning 2,963,066 shares indirectly, and 5AM Opportunities I, L.P. is shown as beneficially owning 1,093,313 shares indirectly. Dr. Parmar may be deemed to share voting and investment power over these positions through general partner entities, but he disclaims beneficial ownership except to the extent of his pecuniary interest.

Entrada Therapeutics, Inc. (TRDA) reported an insider transaction by funds affiliated with 5AM Venture Management. On 11/14/2025, the reporting persons sold 200,000 shares of Entrada common stock at a weighted average price of $8.80 per share, with individual trades executed between $8.80 and $9.023. After this sale, one fund held 2,963,066 shares directly, and another affiliated fund held 1,093,313 shares indirectly. The filing notes that managing members of the general partners may be deemed to share voting and investment power over these holdings and that some of them disclaim beneficial ownership beyond their economic interest.

Entrada Therapeutics (TRDA) filed a Form S-3 shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units, to be sold from time to time after effectiveness. The filing also includes a $150,000,000 at-the-market (ATM) program for common stock via a sales agreement prospectus, which is part of the $400,000,000 aggregate.

The company may sell securities in one or more offerings using various methods described under “Plan of Distribution,” and intends to use any net proceeds for general corporate purposes, including R&D and working capital. Shares outstanding were 38,219,232 as of September 30, 2025. As of the same date, cash, cash equivalents and marketable securities were $326.8 million, which management believes funds operations into the third quarter of 2027.

Entrada Therapeutics (TRDA) filed its Q3 2025 10‑Q, reporting a sharp year-over-year step-down in collaboration revenue and a return to losses as prior-period milestone revenue tapered. Collaboration revenue was $1.6 million for the quarter versus $19.6 million a year ago, and $24.1 million for the nine months versus $173.4 million in 2024. Research and development expenses rose to $38.4 million in Q3 (from $31.3 million), reflecting advancing DMD programs; general and administrative expenses were $10.3 million (from $10.0 million).

The company posted a net loss of $44.1 million for Q3 (vs. $14.0 million loss) and a net loss of $104.6 million year‑to‑date (vs. $64.5 million income), with Q3 EPS of $(1.06). Cash, cash equivalents and marketable securities totaled $326.8 million as of September 30, 2025, which management states is sufficient to fund operations into the third quarter of 2027. Operating cash use was $96.3 million year‑to‑date. Deferred revenue declined to $0.5 million, consistent with revenue recognition on the Vertex collaboration.

Pipeline updates include ongoing Phase 1/2 studies for ENTR‑601‑44 and ENTR‑601‑45 in DMD, UK filing for ENTR‑601‑50, and a planned ENTR‑601‑51 filing in 2026. A 20% workforce reduction in April 2025 resulted in a $1.9 million charge. Shares outstanding were 38,219,232 as of October 31, 2025.

Dipal Doshi, who serves as CEO and a director of Entrada Therapeutics, Inc. (TRDA), reported a sale of 8,723 shares of common stock on 09/02/2025 to cover tax withholding obligations arising from vested restricted stock units. The sale price shown is a weighted average of $5.4302 with reported trade prices ranging from $5.36 to $5.58. After this transaction, the reporting person beneficially owned 415,664 shares directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.

Entrada Therapeutics insider sale to cover RSU taxes The filing shows Nathan J. Dowden, President & COO of Entrada Therapeutics (TRDA), reported a sale of 1,746 shares of common stock on 09/02/2025 at a weighted average price of $5.4302. After the sale he beneficially owned 179,059 shares. The filing states the sale was to satisfy tax withholding obligations arising from vested restricted stock units and was executed in multiple transactions at prices ranging $5.36 to $5.58.

Sethuraman Natarajan, an officer at Entrada Therapeutics, Inc. (TRDA), reported a sale of 1,760 shares of the company's common stock on 09/02/2025 to satisfy tax withholding obligations from vested restricted stock units. The filing shows a weighted-average sale price of $5.4302, with individual trade prices ranging from $5.36 to $5.58. After the reported disposition, the reporting person beneficially owns 197,899 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025. The filing is a routine insider report documenting a tax-withholding sale tied to RSU vesting and does not state any other transactions or derivative holdings.